,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-01-17 08:36:00,"Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Biogen (BIIB) and Home Depot (HD).",0.046168018132448196,0.007902439683675766,0.9459295272827148,neutral,0.03826557844877243
1,2017-01-17 08:36:00,"Buy rated Microsoft shares lagged the Zacks Tech sector through the fall, but have led the way over the last three months (up +8.7% versus +3.3%) on greater appreciation for the company's reorganization and repositioning.",0.9524736404418945,0.025765087455511093,0.021761218085885048,positive,0.9267085790634155
2,2017-01-17 08:36:00,"Notably, estimates have been going up ahead of the company's Q2 earnings release.",0.47329193353652954,0.11061777174472809,0.41609030961990356,positive,0.36267417669296265
3,2017-01-17 08:36:00,"The Zacks analyst points to the company's continuing enterprise strength, benefits from the Office 365 subscription model, strong growth prospects of Azure and promising new products.",0.9253169298171997,0.013410888612270355,0.06127212569117546,positive,0.9119060635566711
4,2017-01-17 08:36:00,The recent acquisition of artificial intelligence startup Maluuba is a big positive for the company given the growing demand for artificial intelligence techniques throughout the world.,0.9154382944107056,0.013851617462933064,0.07071013003587723,positive,0.901586651802063
5,2017-01-17 08:36:00,"Further, the anticipated completion of the LinkedIn acquisition will boost Microsoft's presence in the social media market.",0.949296772480011,0.015611938200891018,0.03509132191538811,positive,0.9336848258972168
6,2017-01-17 08:36:00,"(You can read the full research report on Microsoft here>> )

Biogen shares initially gained from the post-election rally, but have since underperformed the broader pharma space as the macro issues plaguing the space still continue.",0.886441171169281,0.09425526112318039,0.019303640350699425,positive,0.79218590259552
7,2017-01-17 08:36:00,"These issues notwithstanding, the analyst likes the Buy rated stock's strong position in the multiple sclerosis market primarily due to a wide range of products.",0.6924238204956055,0.011391798965632915,0.29618436098098755,positive,0.6810320019721985
8,2017-01-17 08:36:00,Cost cutting efforts and MS franchise sales should continue to drive growth.,0.9244989156723022,0.013813234865665436,0.061687882989645004,positive,0.910685658454895
9,2017-01-17 08:36:00,"Moreover, the upcoming spin-off of the hemophilia business will allow Biogen to focus on the neurology segment, its key area of expertise.",0.6403012275695801,0.009516633115708828,0.3501821756362915,positive,0.6307845711708069
10,2017-01-17 08:36:00,Estimates have also gone up lately ahead of the Q4 earnings results.,0.8259502053260803,0.04115892946720123,0.13289088010787964,positive,0.7847912907600403
11,2017-01-17 08:36:00,The company has a positive record of earnings surprises in recent quarters.,0.9442597031593323,0.02228577248752117,0.03345456346869469,positive,0.9219739437103271
12,2017-01-17 08:36:00,"(You can read the full research report onBiogenhere>> )

Buy rated Home Depot shares have outperformed the Zacks Retail sector over the last three months, gaining +7.4% over the period versus the sector's +0.8% gain in the year-to-date period.",0.9056997895240784,0.07650700211524963,0.017793208360671997,positive,0.8291927576065063
13,2017-01-17 08:36:00,Solid execution and a consistent housing market recovery have been its primary growth drivers.,0.8463457822799683,0.012140084058046341,0.14151409268379211,positive,0.834205687046051
14,2017-01-17 08:36:00,"The analyst likes Home Depot's focus on developing merchandising tools, which, along with investment in building its interconnected capabilities is expected to boost its top line, and enhance market share.",0.9474795460700989,0.015217146836221218,0.03730326518416405,positive,0.9322624206542969
15,2017-01-17 08:36:00,"The company is on track to achieve its long-term dividend payout, share repurchase and return on investment targets.",0.9084774255752563,0.012517848052084446,0.07900471985340118,positive,0.8959595561027527
16,2017-01-17 08:36:00,"Estimates have been stable ahead of the company's Q4 earnings release, while it has positive record of earnings surprises in recent quarters.",0.8989883065223694,0.0522460900247097,0.048765573650598526,positive,0.8467422127723694
17,2017-01-17 08:36:00,"(You can read the full research report onHome Depothere >> )

Other noteworthy reports we are featuring today include 21st Century Fox (FOXA), Bristol-Myers (BMY) and Berkshire Hathaway (BRK.B).",0.033436909317970276,0.005915898364037275,0.9606472253799438,neutral,0.027521010488271713
18,2017-01-17 08:36:00,"In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?",0.017297688871622086,0.008263223804533482,0.9744390845298767,neutral,0.009034465067088604
19,2017-01-17 08:36:00,Who wouldn't?,0.11916464567184448,0.12444141507148743,0.7563939094543457,neutral,-0.005276769399642944
20,2017-01-17 08:36:00,"These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank.",0.17488308250904083,0.010111545212566853,0.815005362033844,neutral,0.16477154195308685
21,2017-01-17 08:36:00,They are our primary picks to buy and hold.,0.06502371281385422,0.004741181619465351,0.9302350878715515,neutral,0.06028253212571144
22,2017-01-17 08:36:00,"Be among the very first to see them >>

Note: Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media.",0.01284050289541483,0.013134380802512169,0.9740250706672668,neutral,-0.00029387790709733963
23,2017-01-17 08:36:00,His weekly earnings related articles include Earnings Trends and Earnings Preview .,0.015174693427979946,0.011023054830729961,0.9738022089004517,neutral,0.004151638597249985
24,2017-01-17 08:36:00,"If you want an email notification each time Sheraz publishes a new article, please click here>>>

Cost Saving & MS Drugs to Push Growth for Biogen (BIIB) in 2017

The Zacks analyst believes Legg Mason is poised to growth through inorganic routes.",0.8544399738311768,0.012620230205357075,0.132939875125885,positive,0.8418197631835938
25,2017-01-17 08:36:00,"However, stringent regulations and continuous fall in assets under management remain concerns.",0.022719215601682663,0.842102587223053,0.13517823815345764,negative,-0.8193833827972412
26,2017-01-17 08:36:00,The covering analyst thinks Moody's advantage lies in its dominant position in the credit rating industry.,0.64927738904953,0.011904241517186165,0.33881834149360657,positive,0.637373149394989
27,2017-01-17 08:36:00,"However, legal issues pertaining to pre-crisis inflated ratings are proving out to be costly.",0.03178040683269501,0.8074582815170288,0.1607612520456314,negative,-0.7756778597831726
28,2017-01-17 08:36:00,The Zacks analyst believes that with improving oil prices Helmerich & Payne will likely get more drilling contracts from upstream energy companies in the coming days.,0.9394340515136719,0.01910441182553768,0.04146161302924156,positive,0.9203296303749084
29,2017-01-17 08:36:00,"The covering analyst thinks Berkshire Hathaway is expected to benefit from its growing Insurance, Manufacturing, Service and Retailing, and Finance and Financial Products segments.",0.8845254182815552,0.01156771183013916,0.10390689224004745,positive,0.872957706451416
30,2017-01-17 08:36:00,"Lowe's (LOW) Strategic Efforts Bode Well for the Long Run

The Zacks analyst thinks strategic efforts, including better omni-channel experience, recent buyouts, such as that of RONA and merchandising initiatives bode well for the company in the long run.",0.8998749256134033,0.013637725263834,0.08648740500211716,positive,0.8862372040748596
31,2017-01-17 08:36:00,The covering analyst thinks Facebook's live video and mobile efforts are big positives along with its subsidiaries.,0.9152820706367493,0.017948774620890617,0.06676913052797318,positive,0.8973333239555359
32,2017-01-17 08:36:00,The Zacks analyst thinks solid restructuring savings are making up for slower revenue growth.,0.7522880434989929,0.18105696141719818,0.06665503233671188,positive,0.5712310671806335
33,2017-01-17 08:36:00,"The Zacks analyst believes that this acquisition will expand Noble Energy's presence in the Permian Basin and offer solid midstream opportunities, supporting its raised production outlook

The covering analyst is impressed by the company's improved Q4 RASM view.",0.9567463994026184,0.017283042892813683,0.025970548391342163,positive,0.9394633769989014
34,2017-01-17 08:36:00,Improved projection was driven by better close-in yields.,0.9371851086616516,0.020092535763978958,0.04272241145372391,positive,0.9170925617218018
35,2017-01-17 08:36:00,The resumption of commercial flights to Havana is also a positive.,0.9138382077217102,0.019242597743868828,0.06691921502351761,positive,0.8945956230163574
36,2017-01-17 08:36:00,The Zacks analyst thinks 21st Century Fox's Cable Network Programming has been driving its performance owing to rising affiliate fees.,0.5156524181365967,0.42868492007255554,0.05566266179084778,positive,0.08696749806404114
37,2017-01-17 08:36:00,The stock has outpaced the industry in the past three months.,0.9134435653686523,0.05409659445285797,0.03245982900261879,positive,0.8593469858169556
38,2017-01-17 08:36:00,"The Zacks analyst feels that stiff competition in the immuno-oncology and HCV markets, along with generic threats for the company's products, will hinder its growth.",0.021044008433818817,0.9617555737495422,0.017200402915477753,negative,-0.9407115578651428
39,2017-01-17 08:36:00,"Stanley Black (SWK) Down to Sell on Lingering Headwinds

Over last one month, Stanley Black's stock has underperformed the Machine Tools & Related Products industry.",0.36505934596061707,0.6032858490943909,0.03165479376912117,negative,-0.2382265031337738
40,2017-01-17 08:36:00,It is facing headwinds like industry rivalry & dismal foreign currency translation.,0.023726528510451317,0.9500938057899475,0.02617969550192356,negative,-0.9263672828674316
41,2017-01-17 08:36:00,"According to the Zacks analyst, lower cyclophosphamide sales are likely to hurt the company's Integrated Pharmacy Solutions business.",0.021204307675361633,0.9613629579544067,0.017432795837521553,negative,-0.9401586651802063
42,2017-01-17 08:36:00,"Furthermore, foreign currency volatility is a headwind.",0.032521411776542664,0.900985836982727,0.0664927139878273,negative,-0.8684644103050232
43,2017-01-17 08:36:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
44,2017-01-17 08:36:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
45,2017-01-17 08:36:00,"Click to get this free report

To read this article on Zacks.com click here.",0.02068457007408142,0.033159855753183365,0.9461556077003479,neutral,-0.012475285679101944
46,2017-01-17 08:36:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
